Compare Adaptive Biotechnologies Corp (ADPT) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs STMicroelectronics NV — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while STMicroelectronics NV trades at $56.39 (market cap $49.21B). The key difference: STMicroelectronics NV is far larger — about 12.2× Adaptive Biotechnologies Corp's market cap, and STMicroelectronics NV pays a 0.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | STM | |
|---|---|---|
Market Cap | $4.04B | $49.21B |
Sector | Health | Financials |
52-Week High | $25.45 | $79.91 |
52-Week Low | $12.30 | $21.20 |
Enterprise Value | $4.10B | $47.21B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
STM trades at $54.35, down 3.12% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.31, beating expectations, but faces declining revenue and net income margins. Analyst consensus is a Buy with a $74.63 price target, supported by strong AI data center growth prospects highlighted in recent earnings calls (Zacks Investment Research, 2026-07-24).
Outlook is mixed; growth catalysts in AI and automotive sectors offer upside potential, but high P/E of 107.92 and recent earnings misses pose valuation and execution risks. Cash flow improved in 2025, yet profitability remains pressured. The stock's near-term direction hinges on Q3 2026 results and demand trends in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
